Valeant Pharmaceutical Calls Critical Research Report ‘False And Misleading’

Shares of the Canadian pharmaceutical company dropped nearly 40 percent Wednesday before rebounding and ending the day down more than 15 percent after short-seller Citron Research accused Valeant of improper accounting and raised questions about its relationship with specialty pharmacies.